IP Library › Granted Patent US 10,905,698
Granted Patent B1
US 10,905,698 · App. 16/921,071 · Granted Feb 2, 2021

Methods of treating SARS-COV-2 infections

Inventors: Steven Hoffman (Mahwah, NJ); John Rothman (Lebanon, NJ)
Assignee: Tyme, Inc.
A61K31/575A01N45/00A61K9/007A61K9/0053A61P31/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,905,698
App. No.
16/921,071
Granted
Feb 2, 2021
Kind
B1
Abstract

The disclosure is directed to methods of using TUDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.

Claims (13)

1. A method of treating COVID-19 in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that is tauroursodeoxycholic acid (TUDCA), or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the agent is TUDCA.

3. The method of claim 1 , wherein the agent is sodium TUDCA.

4. The method of claim 1 , wherein the agent is administered orally.

5. The method of claim 1 , wherein the agent is administered parenterally.

6. The method of claim 1 , wherein the agent is administered via inhalation.

7. The method of claim 1 , wherein the amount of the agent administered to the subject is up to 5 g/day.

8. The method of claim 1 , wherein the agent is administered twice per day.

9. The method of claim 1 , wherein the administration results in a reduction in the subject's SARS-CoV-2 viral load.

10. The method of claim 1 , wherein the administration results in an improvement in one or more of the subject's viral infection symptoms.

11. The method of claim 1 , wherein the administration results in an improvement in the subject's clinical status.

12. The method of claim 1 , wherein the agent is administered after the subject is presenting a symptom of COVID-19.

13. The method of claim 1 , wherein the agent is administered prior to the subject presenting a symptom of COVID-19.

Assignments (2)
SECURITY INTEREST Recorded Dec 5, 2024
From: SYROS PHARMACEUTICALS, INC.; TYME TECHNOLOGIES, INC.; TYME INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 069516/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2020
From: HOFFMAN, STEVEN; ROTHMAN, JOHN
To: TYME, INC.
Reel/Frame 053165/0376 →
Continuity (1)
Provisional Application 63024541 · May 14, 2020